CN108287239B - Application of serum CA2 protein in preparation of liver cancer diagnosis or prognosis evaluation kit - Google Patents
Application of serum CA2 protein in preparation of liver cancer diagnosis or prognosis evaluation kit Download PDFInfo
- Publication number
- CN108287239B CN108287239B CN201711297274.1A CN201711297274A CN108287239B CN 108287239 B CN108287239 B CN 108287239B CN 201711297274 A CN201711297274 A CN 201711297274A CN 108287239 B CN108287239 B CN 108287239B
- Authority
- CN
- China
- Prior art keywords
- liver cancer
- serum
- protein
- kit
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to an application of a serum CA2 protein in preparation of a liver cancer diagnosis or prognosis evaluation kit and the kit. The invention has the following beneficial effects: 1. CA2 can be used as a new liver cancer diagnosis biomarker. 2. The blood detection cost is low, the sample collection and treatment are simple, the repeated sampling can be carried out under any necessary condition to be used as an ideal disease diagnosis and prognosis judgment material, the CA2 can be used as a marker for liver cancer prognosis, and the prognosis of liver cancer is influenced by regulating and controlling the biological function of liver cancer cells.
Description
(I) technical field
The invention relates to an application of a serum CA2 protein in preparation of a liver cancer diagnosis or prognosis evaluation kit and the kit.
(II) background of the invention
Liver cancer is one of common malignant tumors of the digestive system, and has high malignancy, poor prognosis and annual incidence rate. China is a high incidence area of liver cancer, and according to latest statistics of Chinese cancers, new cases and death people of liver cancer in China all live at the top of the world and seriously threaten the health and life of people. At present, the comprehensive treatment mainly based on surgical resection is still the main mode and the most effective means for treating liver cancer, however, the liver cancer is easy to transfer and relapse after operation, the relapse and metastasis rate within 1 year after operation is up to 20-30%, and the relapse and metastasis rate within 5 years is up to 50-70%. Therefore, the biological characteristic of easy metastasis and recurrence of liver cancer is the bottleneck problem of further improving the treatment effect of liver cancer, reducing the death rate of liver cancer and improving the long-term survival rate of liver cancer at present. If the HCC can be predicted and diagnosed as soon as possible and active and effective measures can be taken for prevention and treatment in time before the HCC recurrence and metastasis, the method has important significance for further improving the treatment effect of the liver cancer.
Carbonic Anhydrase II (CA 2) is the most active member in the family of anhydrases, participates in gas transport, acid-base regulation, and tissue secretion, and plays an important role in maintaining the stability of the internal environment. Since CA2 can catalyze CO with high efficiency2Hydration reaction of (2) to produce H + and HCO3-，HCO3-exchange with intracellular Cl-to maintain an intracellular alkaline environment, and transport of intracellular H + out of the cell by means of H + -Na + ion pumps, turning the extracellular environment into an acidic environment. Therefore, CA2 is likely to catalyze CO reversibly2And HCO3-interconversion of (a) into (b), involving acidification of the extracellular microenvironment. This suggests that CA2 can influence tumorigenesis by modulating the pH of the tumor cell microenvironment; whereas the low pH of the extracellular microenvironment is generally considered to be a marker for the abundance of invasiveness and poor prognosis of tumors, changes in the expression level of CA2 have a significant impact on tumorigenesis and its biological behavior.
Disclosure of the invention
The invention aims to research whether CA2 can be used as a marker for liver cancer diagnosis and prognosis, and provides application of serum CA2 protein in preparation of a kit for liver cancer diagnosis or prognosis evaluation and the kit.
The technical scheme adopted by the invention is as follows:
application of a serum CA2(Carbonic Anarase II) protein in preparation of a kit for liver cancer diagnosis or prognosis evaluation.
The invention also relates to a kit for liver cancer diagnosis or prognosis evaluation, which takes the characteristic peptide segment of the serum CA2 protein as a detection marker and mainly comprises the following components: heavy-mark peptide segment (heavy-mark arginine or lysine) synthesized according to characteristic peptide segment of serum CA2 protein13C，15N), detection reagents, and E L ISA kit of CA2 protein.
Specifically, the sequence of the characteristic peptide segment of the serum CA2 protein is GGP L DGTYR or SADFTNFDPR.
The detection reagent is a common reagent in mass spectrometric detection in the field, and comprises PBS (pH7.4), pancreatin (sequencing grade), ammonium bicarbonate (500mM), water (mass spectrometry grade), acetonitrile (chromatography grade) and formic acid.
The E L ISA kit of the CA2 protein can be prepared by self or can adopt a commercial product.
The invention utilizes iTRAQ (interactive tags for relative and absolute quantification, iTRAQ) combined with MS/MS technology to detect the secretory proteins of the cancer tissues, the tissues beside the cancer and the distant tissues of a liver cancer patient and utilizes iTRAQ combined with MS/MS technology to detect the follow-up serum before postoperative recurrence of the liver cancer patient, and commonly discovers a biomarker CA2, wherein the secretion amount of the biomarker CA2 in the liver cancer tissues and the tissues beside the cancer is obviously higher than that of the distant tissues, the secretion of the liver cancer tissues is obviously higher than that of the tissues beside the cancer, the concentration of CA2 protein in the serum before recurrence of the liver cancer patient is obviously higher than that of the serum of a non-recurrence patient, and the E L ISA and Parallel Reaction Monitoring (PRM) verify that the CA2 protein is obviously higher in the serum of the liver cancer patients than that of healthy people and the serum concentration of the non-recurrence patients.
The invention has the main beneficial effects that the invention adopts the quantitative proteomics technology based on the iTRAQ marker, integrates the in vitro secretory proteomics and in vivo serum proteomics data to carry out comprehensive and systematic research on liver cancer patients, provides a new application and a kit of the serum CA2 protein as a liver cancer patient serum diagnosis and prognosis marker, and the marker is verified by E L ISA and mass spectrum PRM, has more reliable results and can provide valuable information for clinical application.
(IV) description of the drawings
FIG. 1 is a flow chart of the work of the liver cancer tissue secretory proteome;
FIG. 2 is a PSM map of peptide fragments GGP L DGTYR and SADFTNFDPR of CA2 protein;
FIG. 3 shows PRM verification results of CA2 mass spectrum;
FIG. 4 shows the concentration of CA2 in serum of PRM patients with liver cancer and healthy persons; p <0.05, P <0.01, P < 0.001;
FIG. 5 is a ROC curve assessment of the sensitivity and specificity of CA2 in liver cancer diagnosis;
FIG. 6 shows the results of E L ISA test for the serum CA2 concentration of patients with recurrent/non-recurrent liver cancer, P <0.05, P <0.01, P < 0.001;
FIG. 7 is a ROC curve of CA2 in diagnosing postoperative recurrence of liver cancer;
FIG. 8 is a Kaplan-Meier method for analyzing the relationship between the CA2 serum concentration and the postoperative recurrence of a liver cancer patient.
(V) detailed description of the preferred embodiments
The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto:
sources of reagents in the examples:
main instrument
Example 1:
the secretory protein group technology detects that the concentration of secretory protein CA2 of cancer tissues of liver cancer patients is obviously higher than the secretory concentration of paracarcinoma tissues and far cancer tissues.
1. Detecting a sample:
selecting secretory protein extracted from tissue culture supernatant of a patient who is treated primarily with liver cancer and is not treated by operation or chemotherapy before surgery in 2013, 11 months to 2014, 12 months in hepatobiliary surgery in Mengtao hepatobiliary Hospital, Fujian medical university.
2. The detection method comprises the following steps:
(1) displacing the lysate, and performing FASP enzymolysis;
(2) extracting a quantitative 100 mu g of secretory proteolysis peptide fragment from the tissue culture supernatant of the patient, respectively marking the mixture of all far cancer tissue secretory proteins by an iTRAQ reagent 113 according to the iTRAQ kit specification for internal reference correction, marking the individual sample by 114 plus 119 (liver cancer tissue, para-cancer tissue and far cancer tissue, 2 biological repetitions), totally marking 5 iTRAQ kits, totally 10 biological repetitions, 10 technical repetitions, mixing and freeze-drying;
(3) desalting the marked peptide section by using a Sep-Pak Vac C18 extraction column;
(4) desalted peptide fragment is 95% H2O + 5% ACN at PH 10, then re-suspended at high PH using an HP L C (high performance liquid chromatography) system connected to a C18 reverse phase column, and 80 tube fractions were collected;
(5) each fraction was treated with 32. mu. L0.1.1% FA + 99.9% H2O, carrying out heavy suspension, nano-liter liquid phase separation and analyzing by using an online electrospray tandem mass spectrometer;
(6) mass spectrum data was searched using Thermo Scientific protome discovery version 1.4 software and matched with UniprotKB human Proteome database;
(7) the bioinformation analysis uses SecretomeP 2.0Server software to detect signal peptide and predict secretory protein; and (3) obtaining a quantitative protein list and the expression quantity of each group of samples of each secretory protein by using Scaffold _4.3.2 software, drawing a protein differential expression spectrum, and screening the significantly differentially expressed secretory protein.
3. And (3) detection results:
CA2 is up-regulated in both C/F group (liver cancer tissue is farther than cancer tissue) and P/F group (para-cancer tissue is farther than cancer tissue), and the ratios of peptide segments in two groups of co-expressed differential secretory proteins are respectively 2.50 and 3.09, which shows that the change of CA2 expression level has important influence on the generation of liver cancer and the biological behavior thereof.
Example 2:
the serum protein technology detects that the concentration of the serum protein CA2 before the recurrence of the liver cancer patient is obviously higher than that of the patient without the recurrence.
1. Detecting a sample:
collecting follow-up serum of 1, 3, 6 and 9 months after radical treatment of 4 liver cancer patients (A, B, C, D) in Mengtao hepatobiliary Hospital, Fujian medical university respectively, extracting 5m L of fasting venous blood from the patients meeting the requirements to a biochemical tube, taking the blood from an ice box, centrifuging the blood at 3000rpm and 4 ℃ for 10 minutes, taking the upper layer of serum, subpackaging and storing the serum in a refrigerator at 80 ℃ below zero.
2. The detection method comprises the following steps:
(1) removing high-abundance protein in serum by using an Agilent multiple affinity removal system MARS-Human 14 liquid chromatographic column;
(2) each group of sera was quantitated at 100. mu.g and trypsinized according to the iTRAQ kit instructions. 2 iTRAQ kits were used, one iTRAQ kit for the low abundance protein peptide of patient A, B and one iTRAQ kit for the low abundance protein peptide of patient C, D. Patient a4 follow-up sera were labeled 113, 114, 115, 116, respectively, and patient B4 was labeled 117, 118, 119, 121, respectively; patient C4 follow-up sera were labeled 113, 114, 115, 116, respectively, and patient D4 follow-up sera were labeled 117, 118, 119, 121, respectively.
(3) Mix dried iTRAQ labeled samples with 95% H2O + 5% ACN, pH 10 redissolving, passing the mixed sample through a C18 reverse phase column into 80 fractions;
(4) and respectively carrying out low-pH value nanoliter liquid chromatography tandem mass spectrometry identification on each fraction.
(5) Mass spectrum data was searched using Thermo Scientific protome discovery version 1.4 software and matched with UniprotKB human Proteome database;
3. and (3) detection results:
the mass spectrum result shows that the concentration of the serum protein CA2 before the recurrence of the liver cancer patient is obviously higher than that of the patient without the recurrence.
Example 3: the concentration of CA2 in the liver cancer patient serum detected by PRM technology is obviously higher than that in the healthy people.
1. Detecting a sample:
PRM analysis is carried out on preoperative serum of HBV related liver cancer patients and matched healthy serum. The number of patients with liver cancer is 49, including 24 recurrent patients and 25 non-recurrent patients. Before the operation, no anti-tumor treatment is performed, and the follow-up data is complete. At the same time, 23 paired healthy human sera were collected as controls.
2. The detection method comprises the following steps:
(1) according to the data of the prophase liver cancer tissue secretory proteomics, the PSM maps of characteristic peptide segments GGP L DGTYR and SADFTNFDPR uniquely expressed by CA2 are selected, and a heavy standard peptide segment (heavy standard arginine 13C15N) is synthesized, and the PSM maps of the characteristic peptide segments GGP L DGTYR (left) and SADFTNFDPR (right) of the CA2 protein are shown in figure 2.
(2) A Multiple affinity exclusion System (MARS) for removing 14 kinds of high-abundance proteins from Human beings by hplc and Agilent corporation was used to remove 14 kinds of high-abundance proteins such as albumin, IgG, and antitrypsin from the serum samples of the liver cancer patients and healthy people to obtain low-abundance proteins, and the proteins were subjected to trypsinization.
(3) The synthesized heavy-label peptide fragment is taken as an internal standard and doped into a serum sample without high-abundance protein, and mass spectrum identification and quantification are carried out by utilizing a targeted quantitative proteomics technology-Parallel Reaction Monitoring (PRM), so as to detect the serum concentration of CA2 in liver cancer patients. The results of the CA2 mass spectrum PRM validation are shown in FIG. 3.
(4) And (3) data analysis: searching a library by using Thermo Scientific proteome scanner 2.1 software for the original data obtained by the PRM, matching with a Uniprot human proteome database (http:// www.uniprot.org/Uniprot), wherein the result can be used as a new database, introducing the original data obtained by the PRM into Skyline software for result analysis with the confidence coefficient of 99%, analyzing the content ratio of the target peptide segment to the re-calibration peptide segment, and comparing the absolute quantitative values of the target peptide segments among groups.
3. And (3) detection results:
as a result, the concentration mean value of CA2 in the serum of liver cancer patients is 13.72pg/m L2, the concentration mean value of CA2 in the serum of healthy people is 6.357pg/m L2, and the concentration of CA2 in the serum of healthy people is respectively obviously higher than that in the serum of normal people (P < 0.01).
Results of ROC curve evaluation of the sensitivity and specificity of CA2 in liver cancer diagnosis are shown in FIG. 5, and as shown in FIG. 5, the area under the curve of the diagnosis CA2 by ROC analysis is 0.715, which has statistical significance (P < 0.05). The diagnostic method shows high sensitivity and good diagnostic specificity.
Example 4 ISA E L ISA test shows that the serum CA2 concentration of patients with liver cancer before relapse is obviously higher than the contemporaneous concentration of patients without relapse
1. Detecting a specimen:
serum samples were taken from post-operative serum from HCC patients who underwent radical resection and regular follow-up in the monto hepatobiliary hospital, university of fujian medical, between 2 months 2014 and 2016 9 months. In total, 82 liver cancer clinical samples were collected, of which 23 patients with non-recurrent liver cancer and 59 patients with recurrent liver cancer. 2. The detection method comprises the following steps:
(1) the E L ISA kit reagents for CA2 protein were slowly equilibrated to room temperature.
(2) Preparing a standard substance according to a Kit, namely adding 1 tube of the standard substance into a standard substance Diluent 1m L, gently mixing the standard substance and the Diluent, standing the mixture at room temperature for 10 minutes to prepare a 20ng/m L standard substance concentrated solution, diluting the standard substance according to the instruction method in turn by times, wherein the standard substance Diluent consists of Sample Diluent (L ife Biosciences, Inc. Human CA2/Carbonic anhydride II E L ISA Kit (Sandwich E L ISA) Catalog NO. L S-F4349).
(3) The preparation of the secondary antibody working solution comprises adding 150 mul of secondary antibody diluent into 1 tube of secondary antibody freeze-dried powder to prepare 100 × concentrated solution, and diluting the secondary antibody concentrated solution by 100 times of the secondary antibody diluent to prepare the secondary antibody working solution before use, wherein the secondary antibody diluent comprises AssayDiluent A (L ife Biosciences, Inc. Human CA2/Carbonic anhydride II E L ISA Kit (Sandwich E L ISA) Catalog NO. L S-F4349).
(4) Preparation of Streptavidin HRP working solution A100-fold dilution of a Streptavidin HRP concentrate was performed just before use, followed by mixing with HRP Diluent consisting of Assay Diluent B (L ifeScan Biosciences, Inc. HumanCA2/Carbonic anhydride II E L ISA Kit (Sandwich E L ISA) Catalog NO. L S-F4349).
(5) Wash preparation 25m L concentrated wash was diluted to 500m L with 475m L distilled water.
(6) The serum was diluted 60-fold with the sample diluent, 100. mu.l of the standard and serum were added to a 96-well microplate in sequence, covered with blocking paper and incubated at 37 ℃ for 2 hours, and the concentrated washing solution consisted of Wash Buffer (30 ×) (L ifeBanbiosciences, Inc. Human CA2/Carbonic Anhydrase II E L ISA Kit (Sandwich E L ISA) Catalog NO L S-F4349).
(7) Discard all liquid and wash 3 times.
(8) Add 100. mu.l of secondary antibody working solution to each well, cover the sealing paper, and incubate at 37 ℃ for 1 hour.
(9) Discard all liquid and wash 3 times.
(10) Add 100. mu.l of HRP working solution to each well, cover the blocking paper, and incubate at 37 ℃ for 30 min.
(11) Discard all liquid and wash 3 times.
(12) Add 100. mu.l of substrate per well, the liquid slowly turns blue and incubate for 10 min at room temperature.
(13) Add 100. mu.l of stop solution to each well and change the solution from blue to yellow.
(14) The OD value was measured with a 450nm wavelength plate reader.
(15) And (3) calculating: and calculating a linear regression equation of the standard curve by using CurveExpert software according to the concentration of the standard substance and the corresponding OD value, and calculating the concentration of CA2 of the sample on the regression equation by using the OD value of the sample.
3. And (3) detection results:
the results showed that the pre-relapse serum concentration of CA2 was significantly higher in the relapsed patients than in the non-relapsed patients, and that the post-operative serum concentration of CA2 was on average 29.96. + -. 10.9ng/m L in the non-relapsed patients, whereas in the post-operative serum of the relapsed patients, it was as high as 48.96. + -. 30.4ng/m L, which were statistically significantly different (P <0.05), see FIG. 6.
The ROC curve of CA2 for diagnosing postoperative recurrence of hepatocarcinoma is shown in FIG. 7 (ROC analysis is performed on the content of CA2 in the serum of patients with recurrence and those without recurrence, the result shows that CA2 has statistical significance (P <0.05), the area under the curve (AUC) is 0.723) in predicting postoperative recurrence of hepatocarcinoma, the relationship between the serum concentration of CA2 and postoperative recurrence of hepatocarcinoma patients is shown in FIG. 8 (by Kaplan-Meier survival curve analysis, whether the serum concentration after CA2 operation is related to postoperative recurrence-free survival rate of HCC patients or not, the result (FIG. 8) shows that the recurrence-free survival rate of CA2 is shown in the group with low concentration of CA2(CA 2<41.8ng/m L), and the recurrence-free survival rate of 10 months, 20 months and 30 months is respectively 50.0%, 44% and 44%, while the recurrence-free survival rate of CA2(CA 2 is not less than 41.8ng/m L) is shown in the group with 10 months, 20 months and 30 months, 17%, 15% and 15.
Claims (2)
1. The application of the characteristic peptide fragment of the serum CA2(Carbonic Anhydrase II) protein in the preparation of the kit for the prognosis evaluation of liver cancer is characterized in that the sequence of the characteristic peptide fragment of the serum CA2 protein is SADFTNFDPR or GGP L DGTYR.
2. A kit for prognosis evaluation of liver cancer mainly comprises a heavy standard peptide segment synthesized according to a characteristic peptide segment of serum CA2 protein and a detection reagent, wherein the sequence of the characteristic peptide segment of the serum CA2 protein is SADFTNFDPR or GGP L DGTYR.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711297274.1A CN108287239B (en) | 2017-12-08 | 2017-12-08 | Application of serum CA2 protein in preparation of liver cancer diagnosis or prognosis evaluation kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711297274.1A CN108287239B (en) | 2017-12-08 | 2017-12-08 | Application of serum CA2 protein in preparation of liver cancer diagnosis or prognosis evaluation kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108287239A CN108287239A (en) | 2018-07-17 |
| CN108287239B true CN108287239B (en) | 2020-07-17 |
Family
ID=62831780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711297274.1A Active CN108287239B (en) | 2017-12-08 | 2017-12-08 | Application of serum CA2 protein in preparation of liver cancer diagnosis or prognosis evaluation kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108287239B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112067807B (en) * | 2019-06-10 | 2022-07-26 | 中国医学科学院肿瘤医院 | Method for screening prognosis related protein from serum of liver cancer patient and application thereof |
| CN114113439A (en) * | 2021-06-17 | 2022-03-01 | 福建医科大学孟超肝胆医院(福州市传染病医院) | Application of serum LRG1 protein in preparation of intrahepatic bile duct cancer lymph node diagnosis kit |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO114835B1 (en) * | 1997-03-17 | 1999-07-30 | Ioan Puşcaş | Method for fast diagnosing cancer |
| WO2007018143A1 (en) * | 2005-08-05 | 2007-02-15 | Ishihara Sangyo Kaisha, Ltd. | Use of gene which varies in amount of expression during the course of transition from precancer to cancer |
| CN101353696A (en) * | 2007-07-24 | 2009-01-28 | 财团法人工业技术研究院 | Biological marker of liver fiber damage including liver fibrosis and/or hepatic cirrhosis and detecting method thereof |
| KR20090052670A (en) * | 2007-11-21 | 2009-05-26 | 전북대학교산학협력단 | A composition for diagnosis of hepatocellular cancer, a diagnosing kit comprising the same, and a method for screening an anticancer agent |
| AU2010208394A1 (en) * | 2009-01-27 | 2011-09-08 | Hologic, Inc. | Biomarkers for detection of neonatal sepsis in biological fluid |
| SE536936C2 (en) * | 2012-04-23 | 2014-11-04 | Rational Enzyme Mining Rem Ab | Human carbohydrate II with increased physical stability |
| CN105349622B (en) * | 2014-08-22 | 2019-05-17 | 南京大学医学院附属鼓楼医院 | GLS is preparing the application in diagnosing cancer of liver and prognosis evaluation reagent kit |
| CN105301259A (en) * | 2015-10-10 | 2016-02-03 | 广西医科大学 | Serum RBP4 (retinol binding protein 4) albumen as liver cancer patient serum marker and application of serum RBP4 albumen |
-
2017
- 2017-12-08 CN CN201711297274.1A patent/CN108287239B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy;Yoshiura K等;《Clnical Cancer Research》;20051130;第11卷(第22期);第8201-8207页 * |
| Immunoprecipitation on magnetic beads and liquid chromatography-tandem mass spectrometry for carbonic anhydrase II quantification in human serum;Callipo,L等;《ANALYTICAL BIOCHEMISTRY》;20100201;第400卷(第2期);第195-202页 * |
| SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma;Luo,YZ等;《SCIENTIFIC REPORTS》;20170124;第7卷;第1-11页 * |
| The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma;Kuo WH等;《Life Sciences》;20030912;第73卷(第17期);第2211-2223页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108287239A (en) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chi et al. | Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS | |
| Li et al. | Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis | |
| Tang et al. | Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer | |
| Chen et al. | Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia | |
| Drake et al. | Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers | |
| Roe et al. | Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study | |
| CA2949753A1 (en) | Methods and marker combinations for screening for predisposition to lung cancer | |
| Zeng et al. | Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry | |
| CN110799841B (en) | Biomarker for detecting colorectal cancer | |
| CN105572355A (en) | Biomarker for detecting esophagus cancer | |
| US20160363560A9 (en) | Metabolite Biomarkers for the Detection of Esophageal Cancer Using NMR | |
| US20230063827A1 (en) | Methods and Compositions for the Diagnosis of Ovarian Cancer | |
| CA2700125A1 (en) | Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast | |
| WO2021076036A1 (en) | Apparatuses and methods for detection of pancreatic cancer | |
| US20160320398A1 (en) | SRM/MRM Assay for Subtyping Lung Histology | |
| CN101424661B (en) | Serodiagnosis model establishing method for active tuberculosis disease | |
| Yang et al. | Identification of novel low molecular weight serum peptidome biomarkers for non‐small cell lung cancer (NSCLC) | |
| CN108287239B (en) | Application of serum CA2 protein in preparation of liver cancer diagnosis or prognosis evaluation kit | |
| US20120295288A1 (en) | Serological marker for detecting pancreatic cancer and a method for using the serological marker | |
| CA3064702A1 (en) | Novel stool-based protein biomarkers for colorectal cancer screening | |
| Li et al. | Exploration of differentially expressed plasma proteins in patients with lung adenocarcinoma using iTRAQ‐coupled 2D LC‐MS/MS | |
| Dai et al. | Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum | |
| CN103224922B (en) | New stomach cancer marker, detection method and applications thereof | |
| Song et al. | MALDI‐TOF‐MS analysis in low molecular weight serum peptidome biomarkers for NSCLC | |
| WO2021116057A1 (en) | Biomarker panel for diagnosing colorectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 350005 tea middle road, Taijiang District, Fuzhou, Fujian Province, No. 20 Applicant after: The First Affiliated Hospital, Fujian Medical University Applicant after: Meng Chao Hepatobiliary Hospital of Fujian Medical University (Fuzhou infectious disease hospital) Address before: 350005 tea middle road, Taijiang District, Fuzhou, Fujian Province, No. 20 Applicant before: The First Affiliated Hospital, Fujian Medical University Applicant before: Meng Chao Hepatobiliary Hospital of Fujian Medical University |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |